<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01696032</url>
  </required_header>
  <id_info>
    <org_study_id>SGI-110-02</org_study_id>
    <nct_id>NCT01696032</nct_id>
  </id_info>
  <brief_title>SGI-110 in Combination With Carboplatin in Ovarian Cancer</brief_title>
  <acronym>SGI-110</acronym>
  <official_title>A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects With Platinum-Resistant Recurrent Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astex Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astex Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 2-part, Phase 2 controlled, open-label, randomized study in patients with
      platinum-resistant recurrent ovarian cancer. In Part 1, patients will receive SGI-110 and
      carboplatin. The optimum dose will be identified in Part 1 based on safety and efficacy. In
      Part 2, patients will be randomized to receive the dose identified in Part 1 plus carboplatin
      or one of three treatment of choice at the discretion of the investigator. The treatment of
      choice consists of topotecan, pegylated liposomal doxorubicin, or paclitaxel.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 (Safety Lead-In): Assess the safety and tolerability of SGI-110 and carboplatin by the incidence of dose limiting toxicities and other adverse events to determine the maximum tolerated dose for Part 2</measure>
    <time_frame>9 months</time_frame>
    <description>Number of patients with adverse events
Incidence of dose limiting toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (Randomized, Controlled, Open Label): Assess and compare progression free survival (PFS) between SGI-110 and carboplatin and Treatment of Choice arms</measure>
    <time_frame>12 months</time_frame>
    <description>Change in CA-125 tumor biomarker every 4 weeks
Change in tumor measurements by RECIST 1.1 every 8 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (complete and partial responses)</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical responses based both on measurable disease and detectable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival at 6 months</measure>
    <time_frame>12 months</time_frame>
    <description>Assessment of progression free survival as measured by weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (complete response + partial response + stable disease for at least 3 months)</measure>
    <time_frame>12 months</time_frame>
    <description>Assessment of clinical benefit rate as measured by weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CA-125 reduction</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of patients with CA-125 reduction by â‰¥ 50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>12 months</time_frame>
    <description>Duration of response measured in weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months</time_frame>
    <description>Overall survival measured in weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of combination treatment of SGI-110 and carboplatin</measure>
    <time_frame>12 months</time_frame>
    <description>Cmax, Cmin, AUC and other secondary PK parameters of SGI-110, decitabine and carboplatin in all patients during Cycle 1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>SGI-110 + Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: Patients will be dosed with SGI-110 and carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SGI-110 + carboplatin or TC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2: Patients will be randomized to receive SGI-110 and carboplatin or Treatment of Choice (TC). TC is at the discretion of the investigator and can be one of three standard of care treatments (topotecan, paclitaxel or pegylated liposomal doxorubicin).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGI-110</intervention_name>
    <arm_group_label>SGI-110 + Carboplatin</arm_group_label>
    <arm_group_label>SGI-110 + carboplatin or TC</arm_group_label>
    <other_name>guadecitabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment of Choice ( topotecan, pegylated liposomal doxorubicin, or paclitaxel)</intervention_name>
    <description>Investigator may choose to treat with either topotecan, pegylated liposomal doxorubicin, or paclitaxel</description>
    <arm_group_label>SGI-110 + carboplatin or TC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>SGI-110 + Carboplatin</arm_group_label>
    <arm_group_label>SGI-110 + carboplatin or TC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who are women 18 years of age or older.

          2. Patients who have histologically or cytologically confirmed recurrent high-grade
             serous epithelial ovarian cancer (Grade 2 or 3), primary peritoneal carcinomatosis or
             fallopian tube cancer.

          3. Patients who have platinum-resistant disease (defined as having relapsed within 6
             months of her last platinum-containing regimen). There is no limit on the number of
             prior treatment regimens in Part 1. In Part 2, patients may have had no more than 3
             prior cytotoxic treatment regimens, excluding adjuvant or maintenance therapy.

          4. Patients must have had prior paclitaxel treatment.

          5. Patients who have measurable disease according to RECIST v1.1 or detectable disease.

          6. Patients with ECOG performance status of 0 or 1.

          7. Patients with acceptable organ function.

          8. Patients must be at least 3 weeks from last chemotherapy.

        Exclusion Criteria:

          1. Patients who have hypersensitivity to SGI-110 and/or carboplatin or other components
             of these drug products.

          2. Patients who have received prior therapy with any hypomethylating agents.

          3. Patients who are refractory to platinum treatment i.e., progressed while on platinum
             treatment.

          4. Patients with abnormal left ventricular ejection fraction.

          5. Patients with Grade 2 or greater neuropathy.

          6. Patients with known brain metastases.

          7. Patients with known history of HIV, HCV or HBV.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Norris Comprehensive Cancer Center- University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Shands Cancer Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Health Sciences University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melvin and Bren Simon Cancer Center- Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Cancer Care</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Island Gynecologic Oncology</name>
      <address>
        <city>Brightwaters</city>
        <state>New York</state>
        <zip>11718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute- Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Cancer Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Medical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM Gynecologie-Oncologie, Notre Dame Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Heamatology and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James Univesity Hospital - St. James Institute of Oncology</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation and Trust</name>
      <address>
        <city>London</city>
        <zip>EC1V 4AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univesity College Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Health Care NHS Trust-Garry Weston Centre</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre</name>
      <address>
        <city>Middlesex</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2012</study_first_submitted>
  <study_first_submitted_qc>September 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2012</study_first_posted>
  <disposition_first_submitted>January 15, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>January 15, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 18, 2018</disposition_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

